Two diabetes drugs could treat fatty liver disease
Data from trials show that two diabetes drugs show an ability to treat non-alcoholic steatohepatitis (NASH), a form of fatty liver disease. The drugs which showed this ability were liraglutide (Victoza) and remogliflozin etabonate.
Whereas liraglutide, a GLP-1 receptor agonist, has been approved for treating type 2 diabetes for a number of years, remogliflozin etabonate, an SGLT-2 inhibitor, is a newer drug that has not received approval from the FDA.
The LEAN (Liraglutide Efficacy and Action in Nonalcoholic Steatohepatitis) trial was a 48 week study that reviewed the effects of liraglutide on liver health. The trial used a daily 1.8 mg dose of Victoza and compared the effects of the drug against placebo in patients with nonalcoholic steatohepatitis. The results showed that 39% those taking Victoza experienced improvement in their liver health, compared with 9% in the placebo group.
In another trial, the drug remogliflozin etabonate was tested against placebo. The 12 week study, which included 336 patients with type 2 diabetes, showed the drug to have greater antioxidant activity than other SGLT-2 inhibitor drugs that have been approved. The lower level of markers for oxidative stress indicates that remogliflozin etabonate may also be well suited to patients with non-alcoholic steatohepatitis.
The data was presented at the European Association for the Study of the Liver International Liver Congress 2015 in Vienna. Dr Markus Peck-Radosavljevic, who moderated during the news conference, noted that the beneficial effects could well have been down to the effects of weight loss brought on by both liraglutide and remogliflozin etabonate.
Add A Comment
- Meta-analysis uncovers potential glucose lowering of Aloe Vera: https://t.co/29fykT54F0